| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2004) |
| Entry Type: | Unknown |
| Molecule Category: | Salt |
| UNII: | 3HP012Q0FH |
| Parent Compound: | PEGAPTANIB |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Vascular endothelial growth factor A antagonist | DailyMed |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Macular Edema | 3 | D008269 | ClinicalTrials |
| Macular Degeneration | 3 | D008268 | ClinicalTrials |
| Macular Degeneration | 3 | D008268 | ClinicalTrials |
| Retinal Vein Occlusion | 2 | D012170 | ClinicalTrials |
| von Hippel-Lindau Disease | 1 | D006623 | ClinicalTrials |
Related Entries
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 222716-86-1 |
| ChEMBL | CHEMBL1201421 |
| FDA SRS | 3HP012Q0FH |
CONTENTS